
## Vaskar Saha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3792353/publications.pdf Version: 2024-02-01



VASKAD SAHA

#	Article	IF	CITATIONS
1	Reply to: Comment on: Unsatisfactory quality of E. coli asparaginase biogenerics in India—Implications for clinical outcomes in acute lymphoblastic leukaemia. Pediatric Blood and Cancer, 2022, 69, e29334.	0.8	1
2	Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India. Trials, 2022, 23, 102.	0.7	26
3	Activity and toxicity of intramuscular 1000 <scp>iu</scp> /m <sup>2</sup> polyethylene glycol― <i>E. coli</i> <scp>Lâ€esparaginase</scp> in the <scp>UKALL</scp> 2003 and <scp>UKALL</scp> 2011 clinical trials. British Journal of Haematology, 2022, , .	1.2	3
4	Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 843.	3.8	166
5	Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia. Pediatric Blood and Cancer, 2021, 68, e29046.	0.8	11
6	Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. European Journal of Cancer, 2021, 151, 175-189.	1.3	27
7	Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia—a report from the UKALL 2011 trial. European Journal of Cancer, 2019, 120, 75-85.	1.3	18
8	Efficacy and safety of a bortezomib and reducedâ€intensity cytarabineâ€based protocol, TMC ALLR1, for relapsed childhood ALL in India. British Journal of Haematology, 2019, 186, 861-865.	1.2	9
9	Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Lancet Haematology,the, 2019, 6, e204-e216.	2.2	36
10	The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. Health Economics Review, 2019, 9, 40.	0.8	7
11	Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. Haematologica, 2019, 104, e13-e16.	1.7	19
12	Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica, 2018, 103, 107-115.	1.7	68
13	Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematology,the, 2018, 5, e641-e652.	2.2	78
14	A tripleâ€probe FISH screening strategy for riskâ€stratified therapy of acute lymphoblastic leukaemia in lowâ€resource settings. Pediatric Blood and Cancer, 2018, 65, e27366.	0.8	10
15	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood, 2017, 129, e26-e37.	0.6	195
16	Acute lymphoblastic leukaemia cells produce large extracellular vesicles containing organelles and an active cytoskeleton. Journal of Extracellular Vesicles, 2017, 6, 1294339.	5.5	34
17	Relapsed Acute Lymphoblastic Leukemia of Childhood. , 2017, , 255-297.		1
18	Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia. Haematologica, 2017, 102, 1075-1084.	1.7	8

VASKAR SAHA

#	Article	IF	CITATIONS
19	SOX7 promotes the maintenance and proliferation of B cell precursor acute lymphoblastic cells. Oncotarget, 2017, 8, 64974-64983.	0.8	5
20	Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia. PLoS ONE, 2017, 12, e0178606.	1.1	4
21	Mixed-phenotypic acute leukemia series from tertiary care center. Indian Journal of Pathology and Microbiology, 2017, 60, 43-49.	0.1	9
22	Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia. Blood, 2016, 128, 453-456.	0.6	60
23	Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood, 2016, 128, 911-922.	0.6	103
24	EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood, 2016, 127, 2214-2218.	0.6	108
25	Development of a selected reaction monitoring mass spectrometry-based assay to detect asparaginyl endopeptidase activity in biological fluids. Oncotarget, 2016, 7, 70822-70831.	0.8	10
26	Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. European Journal of Cancer, 2015, 51, 218-224.	1.3	80
27	Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol. Blood, 2015, 126, 1414-1414.	0.6	1
28	Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia. Oncotarget, 2015, 6, 43048-43064.	0.8	35
29	IKZF1 status as a prognostic feature in BCR-ABL1–positive childhood ALL. Blood, 2014, 123, 1691-1698.	0.6	129
30	Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. PLoS ONE, 2014, 9, e108107.	1.1	34
31	Microbiology, infection control and infection related outcome in pediatric patients in an oncology center in Eastern India: Experience from Tata Medical Center, Kolkata. Indian Journal of Cancer, 2014, 51, 415.	0.2	9
32	Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2012, 366, 1371-1381.	13.9	252
33	Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncology, The, 2012, 13, 936-945.	5.1	282
34	Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood, 2011, 117, 1614-1621.	0.6	122
35	Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia. Blood, 2011, 117, 6247-6254.	0.6	86
36	RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. Blood, 2011, 118, 638-649.	0.6	49

VASKAR SAHA

#	Article	IF	CITATIONS
37	Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia. , 2011, , 25-37.		Ο
38	Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. Journal of Clinical Oncology, 2010, 28, 4755-4761.	0.8	203
39	Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet, The, 2010, 376, 2009-2017.	6.3	282
40	A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginase. Journal of Clinical Investigation, 2009, 119, 1964-73.	3.9	69
41	Simplifying treatment for children with ALL. Lancet, The, 2007, 369, 82-83.	6.3	4
42	Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8167-8172.	3.3	146
43	Non-Hodgkin's Lymphomas of Childhood. , 2006, , 502-525.		1
44	Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. British Journal of Haematology, 2005, 129, 35-44.	1.2	44
45	LISA: a web-based decision-support system for trial management of childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2005, 129, 746-754.	1.2	34
46	Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. British Journal of Haematology, 2005, 130, 26-35.	1.2	39
47	Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. British Journal of Haematology, 2005, 130, 67-75.	1.2	117
48	Philadelphia positive acute lymphoblastic leukaemia of childhood. British Journal of Haematology, 2005, 130, 489-500.	1.2	49
49	QUALIFIED PREDICTIONS FOR MICROARRAY AND PROTEOMICS PATTERN DIAGNOSTICS WITH CONFIDENCE MACHINES. International Journal of Neural Systems, 2005, 15, 247-258.	3.2	37
50	Molecular Techniques to Improve Outcome in Childhood ALL. , 2004, 91, 111-122.		1
51	TEL Deletion Analysis Supports a Novel View of Relapse in Childhood Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2004, 10, 5355-5360.	3.2	66
52	Response to Piel etÂal. British Journal of Haematology, 2004, 125, 412-412.	1.2	2
53	Molecular Characterization of AML1 (RUNX1) Amplification: A Poor Risk Chromosomal Marker in Acute Lymphoblastic Leukaemia (ALL) Blood, 2004, 104, 140-140.	0.6	5
54	Early Response to Induction Is Predictive of Survival in Childhood Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia: Results of the Medical Research Council ALL 97 Trial Blood, 2004, 104, 165-165.	0.6	1

VASKAR SAHA

#	Article	IF	CITATIONS
55	Expression profile of wild-type ETV6 in childhood acute leukaemia. British Journal of Haematology, 2003, 122, 94-98.	1.2	30
56	Routine blood counts in children with acute lymphoblastic leukaemia after completion of therapy: are they necessary?. British Journal of Haematology, 2003, 122, 451-453.	1.2	8
57	Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. British Journal of Haematology, 2003, 123, 100-102.	1.2	58
58	Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. British Journal of Haematology, 2002, 117, 821-827.	1.2	107
59	Chromatin Modification, Leukaemia and Implications for Therapy. British Journal of Haematology, 2002, 118, 714-727.	1.2	45
60	Cytogenetic and molecular evidence of marrow involvement in extramedullary acute myeloid leukaemia. British Journal of Haematology, 2000, 110, 547-551.	1.2	18
61	MEDICAL MANAGEMENT OFASPERGILLUS FLAVUSENDOCARDITIS. Pediatric Hematology and Oncology, 2000, 17, 425-427.	0.3	27
62	The cloning, mapping and expression of a novel gene, BRL, related to the AF10 leukaemia gene. Oncogene, 1999, 18, 7442-7452.	2.6	20
63	Expression pattern and cellular distribution of the murine homologue of AF10. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1443, 285-296.	2.4	23
64	Translocations, fusion genes, and acute leukemia. , 1998, 72, 264-276.		17
65	Late-Onset Hemorrhagic Cystitis Following Bone Marrow Transplantation: A Case Report. Pediatric Hematology and Oncology, 1997, 14, 273-275.	0.3	5
66	Gene BRI40, Which is Related to AF1O and AF17, Maps to Chromosome Band 3p25. Genes Chromosomes and Cancer, 1996, 17, 269-272.	1.5	4
67	Increased radiosensitivity in a child with T-cell non-Hodgkin's lymphoma. , 1996, 27, 565-570.		5
68	AF6 gene on chromosome band 6q27 maps distal to the minimal region of deletion in epithelial ovarian cancer. Genes Chromosomes and Cancer, 1995, 14, 220-222.	1.5	9
69	Anaplastic large cell lymphoma in childhood. Medical and Pediatric Oncology, 1993, 21, 665-670.	1.0	12
70	An odyssey in search of a cure: The evolution of treatment of childhood acute lymphoblastic leukemia in the United Kingdom. Indian Journal of Pediatrics, 1993, 60, 525-538.	0.3	2
71	The Treatment of Pseudomonas aeruginosa Meningitis Old Regime or Newer Drugs?. Scandinavian Journal of Infectious Diseases, 1993, 25, 81-83.	1.5	5
72	Long-Term Prednisolone Therapy in Children with Idiopathic Pulmonary Hemosiderosis. Pediatric Hematology and Oncology, 1993, 10, 89-91.	0.3	2

#	Article	IF	CITATIONS
73	Induction Regimens in Acute Myeloid Leukemia. , 0, , 221-239.		Ο

Role of Maintenance Treatment in Childhood Acute Myeloid Leukemia. , 0, , 250-278.

0